Design Therapeutics director files Form 3

Design Therapeutics, Inc. filed a Form 3 insider report identifying David Shapiro as a director of the company.

Rhea-AI Filing Summary

Design Therapeutics, Inc. filed a Form 3 insider report identifying David Shapiro as a director of the company. The provided data shows no reportable transactions or holdings, indicating this filing serves only to register his status as a reporting person.

Key Terms

Form 3, reportingPersons, transactionSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Shapiro David""

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for DSGN show about David Shapiro?

The Form 3 filing lists David Shapiro as a director of Design Therapeutics, Inc. It establishes him as a reporting person for SEC purposes but, in the provided data, does not detail any specific shareholdings or transactions.

Are any share transactions reported in David Shapiro’s DSGN Form 3?

No transactions are reported in this Form 3 for Design Therapeutics, Inc.. The transaction summary fields all show zero counts, indicating no buys, sells, exercises, gifts, or other trades in the provided data.

Does the DSGN Form 3 disclose how many shares David Shapiro owns?

The provided Form 3 data for Design Therapeutics, Inc. does not list any specific holdings for David Shapiro. Holding-related entries are shown as zero, so no share amounts or option positions are disclosed here.

What is the significance of a Form 3 for Design Therapeutics (DSGN)?

A Form 3 identifies an insider as a reporting person for SEC purposes. For Design Therapeutics, Inc., it formally records David Shapiro’s director status, although this particular dataset includes no trades or ownership quantities.

Does the DSGN Form 3 include any derivative positions or options?

The provided Form 3 data for Design Therapeutics, Inc. shows no derivative entries. The derivative summary is empty, and the transaction summary lists zero derivative transactions or exercises in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shapiro David

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CALIFORNIA 92011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/31/2026

3. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Mustapha Parekh, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)